Stephen Russell, Ph.D., Mayo Clinic
- Jan 25, 2017
- Topic: [tbd]
- Date: Wednesday, February 1, 2017
- Time: 12n-1p
- Place: B448 Life Science Bldg
"The research interests of Stephen J. Russell, M.D., Ph.D., center on demonstrating the value of oncolytic virotherapy as a new modality for the treatment of cancer. Viruses from several families are engineered in Dr. Russell's laboratory. His team currently has oncolytic projects focusing on measles, vesicular stomatitis virus (VSV), coxsackievirus A21 (CVA21) and Mengo virus. Nonreplicative adeno-associated viruses, lentivirus and adenovirus vectors also are used extensively.
Dr. Russell's long-term research goals are to develop genetically engineered oncolytic viruses that are selectively destructive to a variety of disseminated cancers, to elucidate the molecular targeting mechanisms that govern their cancer specificity, and to advance them to clinical testing." - excerpted from his faculty page at http://mayo.edu